Palmar-plantar erythrodysesthesia: An uncommon adverse effect of everolimus.

about

Palmar-plantar erythrodysesthesia: An uncommon adverse effect of everolimus.

Item

http://www.wikidata.org/entity/Q36861416

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Palmar-plantar erythrodysesthesia: An uncommon adverse effect of everolimus.

@en

type

Item

label

Palmar-plantar erythrodysesthesia: An uncommon adverse effect of everolimus.

@en

prefLabel

Palmar-plantar erythrodysesthesia: An uncommon adverse effect of everolimus.

@en

P1476

Palmar-plantar erythrodysesthesia: An uncommon adverse effect of everolimus.

@en

P2093

Rajendra Akhil

http://www.w3.org/2001/XMLSchema#string

Raju Titus Chacko

http://www.w3.org/2001/XMLSchema#string

Renu George

http://www.w3.org/2001/XMLSchema#string

Shalabh Arora

http://www.w3.org/2001/XMLSchema#string

P2860

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

mTOR and cancer: many loops in one pathway.

ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms.

Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.

Rash to the mTOR inhibitor everolimus: systematic review and meta-analysis.

A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure.

Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance.

Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.

Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells.

P304

116-118

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.4103/0971-5851.180143

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27168711

http://www.w3.org/2001/XMLSchema#string

P932

4854043

http://www.w3.org/2001/XMLSchema#string